Skip to main content

Advertisement

SpringerLink
Log in

Rituximab in CD20 positive multiple myeloma

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fonseca R . Many and multiple myeloma(s). Leukemia 2003; 17: 1943–1944.

    Article  CAS  Google Scholar 

  2. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ . The (11;14)(q13;q32) in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000; 113: 831–837.

    Article  CAS  Google Scholar 

  3. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R . t(11 ;14) and t(4 ;14) Translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17: 2032–2035.

    Article  CAS  Google Scholar 

  4. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071.

    Article  CAS  Google Scholar 

  5. Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner JE et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 1992; 64: 132–139.

    Article  CAS  Google Scholar 

  6. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer H, Shima Y et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72–81.

    Article  Google Scholar 

  7. Niklas Z, Kirchbacher K, Vesely M, Hübl W, Ludwig H . Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006; 47: 1103–1109.

    Article  Google Scholar 

  8. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  Google Scholar 

  9. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB . Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellualr cytotoxicity. Clin Cancer Res 2006; 12: 4027–4035.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Roche Pharmaceuticals, Neuilly-sur-Seine, France.

Author information

Authors and Affiliations

  1. Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

    P Moreau & J L Harousseau

  2. Hematology Department, University Hospital Jean Minjoz, Besan, ç, on, France

    L Voillat

  3. Hematology Department, University Hospital Bretonneau, Tours, France

    L Benboukher

  4. Hematology Laboratory, Institut Curie, Paris, France

    C Mathiot

  5. Hematology Department, University Hospital Lyon Sud, Pierre Bénite, France

    C Dumontet

  6. Hematology Laboratory, University Hospital Hôtel-Dieu, Nantes, France

    N Robillard, R Garand & H Avet-Loiseau

  7. Hematology Laboratory, University Hospital Bretonneau, Tours, France

    O Hérault

  8. Hematology Laboratory, University Hospital Jean Minjoz, Besan, ç, on, France

    F Garnache

  9. Laboratoire Roche, Bd du Parc, Neuilly-sur-Seine, France

    N Varoqueaux

  10. Centre Gauducheau, Hôpital Nord, Saint-Herblain, France. E-mail: philippe.moreau@chu-nantes.fr,

    R Bataille

Authors
  1. P Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Voillat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Benboukher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Mathiot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Dumontet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Robillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O Hérault
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Garnache
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Garand
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N Varoqueaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Avet-Loiseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J L Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Bataille
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the IFM group

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moreau, P., Voillat, L., Benboukher, L. et al. Rituximab in CD20 positive multiple myeloma. Leukemia 21, 835–836 (2007). https://doi.org/10.1038/sj.leu.2404558

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404558

  • Springer Nature Limited

This article is cited by

Search

Navigation